Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if VedAryo tames IBD Flare-Ups

NCT ID NCT07273760

Disease control Sponsor: AryoGen Pharmed Co. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 150 people with inflammatory bowel disease (ulcerative colitis or Crohn's disease) who were given VedAryo (vedolizumab) to see if it helps control their condition and is safe. Participants received the drug by IV at the start, after 2 weeks, after 6 weeks, and then every 8 weeks for a year. The main goal was to see how many had fewer symptoms at 52 weeks, and researchers also tracked any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vedolizumab (VedAryo)
What this could lead to
If successful, this study could confirm that VedAryo is a safe and effective option for controlling inflammatory bowel disease symptoms.
What could go wrong
This is an observational study with no comparison group, so results are less reliable. It only follows 150 people for 52 weeks, so long-term safety and effectiveness are not fully assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Jul 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Primary care clinic

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with Inflammatory bowel disease, including Ulcerative Colitis and Crohn's disease * Patients with an indication of vedolizumab therapy * Ability to comprehend and willingness to sign the informed consent form for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease (CD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease (CD) Inflammatory bowel disease (IBD) Ulcerative colitis (UC)

Contacts and locations

Locations

  • Dr. Ali Beheshti-Namdar Clinic

    Mashhad, Razavi Khorasan Province, Iran

  • Dr. Hamid Asadzadeh Aghdaei Clinic

    Tehran, Iran

  • Dr. Hassan Vossoughinia Clinic

    Mashhad, Razavi Khorasan Province, Iran

  • Dr. Mahtab Shabani Clinic

    Tehran, Iran

  • Dr. Mohammad-Javad Kaviani Clinic

    Shiraz, Fars, Iran

  • Dr. Naser Ebrahimi Daryani Clinic

    Tehran, Iran

  • Gilan Gastroenterology and Hepatology Subspecialty Clinic

    Rasht, Gilan Province, Iran

  • Imam Khomeini Hospital

    Tehran, Iran

  • Mehr Specialty Clinic

    Tehran, Iran

  • Professor Shahram Agah Gastroenterology, Hepatology, and Endoscopy Subspecialty Clinic

    Tehran, Iran

  • Shariati Hospital

    Tehran, Iran

  • Taleghani Hospital

    Tehran, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.